Advertisement

Related Videos

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Welcome and Introduction to Vi3C

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Advertisement

Advertisement




May
05
Today In Oncology
AI Shows Dermatologist-Level Accuracy in Melanoma Diagnosis but Needs Validation
CLL Linked to Increased Skin Cancer Risk and Mortality
COA and Flatiron Health Study Finds Patients May Experience Longer Survival in Community Oncology Settings
Zoldonrasib in Patients With KRAS G12D NSCLC Previously Treated With Chemoimmunotherapy
Early-Onset ICI-Related Myocarditis Linked to Increased Mortality
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo